Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
18/10/2023 13:24
Oct 18 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO ANNOUNCES CORPORATE UPDATE
* BAUDAX BIO INC - PHASE 1/2A CLINICAL STUDY OF TI-168 IN
HEMOPHILIA A WITH FVIII INHIBITORS PROJECTED TO BEGIN Q1 2024
* BAUDAX BIO INC - TO INITIATE TI-168 CLINICAL DEVELOPMENT
FOLLOWING RECENT SHAREHOLDER APPROVAL OF CORPORATE ACTIONS
RELATED TO TERAIMMUNE ACQUISITION
Source text for Eikon: ID:nGNX2KV1QY
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer